Advocacy, Biologics4 months agoBiologic Therapy Documentation: How Better Front-End Processes Can Support Cleaner Claims
Advocacy, Biologics4 months agoProlia® Biosimilar Approval Signals Continued Growth in Specialty Biosimilars
Advocacy, Biologics5 months agoRemedy GPO 2026 Mid-Year Update: Celebrating Growth Across Our Network
Advocacy, Biologics5 months agoReducing Infusion No-Shows and Late Cancellations: Practical Strategies for Specialty Practices to Protect Capacity and Revenue
Advocacy, Biologics6 months agoThe Next Front in Drug Pricing: What Medicare Drug Negotiation Means for Buy-and-Bill Infusion Practices
Advocacy, Biologics7 months agoHarnessing Patient Experience Data to Improve Infusion Practice Performance
Advocacy, Biologics8 months ago2026 PBM Formulary Exclusions: What Independent Practices Need to Know About Biosimilars, Net Pricing, and Market Access
Advocacy, Biologics9 months agoFaster Rituximab Infusions in Rheumatology: Evidence Supports Safe, Efficient Care Delivery
Advocacy, Biologics10 months agoOptimizing Infusion Center Capacity in 2026: Strategies to Do More Without Expanding Footprint
Advocacy, Biologics10 months agoBiosimilar Adoption in 2026: What Every Specialty Practice Needs to Know
Advocacy11 months agoVertical Integration and the Future of Buy-and-Bill: How Wholesalers Are Rewriting Market Access
Advocacy1 year agoAccumulator and Maximizer Programs: What Specialty Providers Need to Know About the Hidden Costs for Patients
Advocacy1 year agoBeyond the Bag: Building Operational Resilience in Your Buy-and-Bill Infusion Model
Advocacy1 year agoPrivate Labels, Public Consequences: Making Sense of the Stelara Biosimilar Market in 2025
Advocacy1 year agoIs Your Infusion Suite Future-Ready? Infrastructure, Staffing, and Payer Trends to Watch
